Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Bierman

Gastroenterology Harvey, IL Medical Doctor

NPI 1144245234 CMS profile 97440

1 Ingalls Dr, Harvey, IL 60426

Open in the dashboard

General payments

$21,928

475 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Bierman of Harvey, IL is reported in the CMS Open Payments database as having received $21,928 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,809 99
2024 General $1,709 101
2023 General $1,514 89
2022 General $1,453 84
2021 General $33 2
2020 General $389 20
2019 General $15,021 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Bierman
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Paul Bierman were reported at $1,809. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Paul Bierman Gastroenterology median Middle half National median
2019 $15,021 $417 $126–$1,100 $163
2020 $389 $224 $74–$624 $114
2021 $33 $352 $106–$1,054 $132
2022 $1,453 $448 $129–$1,270 $149
2023 $1,514 $533 $150–$1,390 $160
2024 $1,709 $605 $160–$1,606 $164
2025 $1,809 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $11,819 38 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,365 58 payments
  3. AbbVie, Inc. $1,945 138 payments
  4. Gilead Sciences, Inc. $569 28 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $569 29 payments
  6. Olympus America Inc. $362 5 payments
  7. Genzyme Corporation $360 14 payments
  8. Ironwood Pharmaceuticals, Inc $244 16 payments
  9. Pfizer Inc. $232 15 payments
  10. Janssen Biotech, Inc. $221 11 payments
  11. Other $2,243 123 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,400 6 payments
  2. Food and Beverage $8,120 467 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,400 1 payment
  4. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. ZENPEP $9,011 6 payments
  2. LINZESS $3,248 65 payments
  3. TRULANCE $2,564 8 payments
  4. VIBERZI $2,474 32 payments
  5. RINVOQ $761 52 payments
  6. XIFAXAN $693 44 payments
  7. CREON $455 35 payments
  8. SKYRIZI $443 32 payments
  9. ENTYVIO $428 21 payments
  10. DUPIXENT $360 14 payments
  11. Other $4,781 263 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,195

Median for Gastroenterology: 569

Drug cost

$476,637

Median for Gastroenterology: $104,976

Branded share of claims

29%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 138 $118,485
Rinvoq Upadacitinib Brand 13 $83,829
Xifaxan Rifaximin Brand 20 $71,859
Creon Lipase/Protease/Amylase Brand 27 $48,121
Zenpep Lipase/Protease/Amylase Brand 17 $27,318
Viberzi Eluxadoline Brand 14 $20,338
Movantik Naloxegol Oxalate Brand 21 $15,655
Lubiprostone Generic 69 $12,576
Mesalamine Generic 36 $10,732
Alosetron Hcl Generic 11 $9,692

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$206,571

Medicare's payments for the services billed

Medicare patients

1,044

Average age 74

Services billed

2,567

600 women, 444 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 44%
Diabetes 42%
Chronic kidney disease 39%
Heart failure 30%
Depression 29%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$189 13 —
SKYRIZI
$143 — —
DUPIXENT
$122 — —
XIFAXAN
$113 20 —
LINZESS
$89 138 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record